Compare KE Holdings Inc (BEKE) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KE Holdings Inc vs TransMedics Group Inc — how do they compare? KE Holdings Inc trades at $17.38 (market cap $18.92B), while TransMedics Group Inc trades at $86.89 (market cap $3.10B). The key difference: KE Holdings Inc is far larger — about 6.1× TransMedics Group Inc's market cap, and KE Holdings Inc pays a 1.63% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| BEKE | TMDX | |
|---|---|---|
Market Cap | $18.92B | $3.10B |
Sector | Technology | Technology |
52-Week High | $20.36 | $150.42 |
52-Week Low | $14.26 | $61.99 |
Enterprise Value | $14.66B | $3.49B |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BEKE trades at $17.335, down 1.78% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent Q1 2026 earnings beat expectations with EPS of $0.20 versus $0.14, driven by cost controls and operational efficiency. Revenue for 2025 was $94.58 billion, with a net income margin of 3.76%, though cash flow from operations was negative $376.17 million.
The outlook is positive given analyst support and potential trend reversal from oversold conditions, but risks include reliance on China's property market and volatile cash flows. The stock presents a growth opportunity if operational improvements continue, yet investors face exposure to macroeconomic and regulatory headwinds in the housing sector.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KE Holdings Inc
KE Holdings (Beike) is China’s leading platform for housing transactions and services. It operates the Lianjia brand and uses data-driven technology to facilitate home sales, rentals, and home renovation services.
Read more on BEKE →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
